Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Urothelial Carcinoma
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
The purpose of this study is to assess the antitumor activity of avelumab in combination with tuvusertib in terms of objective response in participants with advanced urothelial carcinoma.
- Trial name
- NCT06424717
- Testing
- Avelumab, Tuvusertib
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Bladder Cancer
3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT01124682
- Testing
- diagnostic cystoscopy, diffusion-weighted magnetic resonance imaging, implanted fiducial-based imaging
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Bladder Cancer Stage IV
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
- Trial name
- NCT04562311
- Testing
- Chidamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Transitional Cell Carcinoma
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the…
- Trial name
- NCT00070070
- Testing
- TICE®-strain BCG, NY-ESO-1 protein, sargramostim
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Urologic Diseases, Hematuria
A Study of Ward Admissions for Haematuria
This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus…
- Conditions
- Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer
- Trial name
- WASHOUT (NCT07395037)
- Testing
- Inpatient work-up and management
- Where
- United Kingdom
- Volunteers
- 1,050 people
- Sponsor
- British Urology Researchers in Surgical Training
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01118039
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 4 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Hospital del Mar
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma
- Trial name
- NCT04579224
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 448 sites in United States
- Volunteers
- 131 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268450
- Testing
- bevacizumab, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Radical Cystectomy, Urothelial Carcinoma
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in preoperative neoadjuvant treatment of MIBC…
- Trial name
- NCT05723991
- Testing
- Disitamab Vedotin and Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Chunguang yang (101937)
Melanoma, Urothelial Carcinoma
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive…
- Trial name
- NCT05496192
- Testing
- Nivolumab/rHuPH20, Nivolumab
- Where
- 3 sites in Germany, Spain
- Sponsor
- Bristol-Myers Squibb
Urinary Bladder Neoplasms
Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure
This is a Phase I, open-label, multicenter, dose-escalation study that aims to evaluate the safety and tolerability of intravesical inactivated Instillations of UPEC-FimON (Uro-Pathogenic E.
- Trial name
- NCT07881666
- Testing
- Inactivated UPEC-FimON
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Hopec Pharma
Metastatic Urothelial Carcinoma
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer.
- Trial name
- NCT04863885
- Testing
- Ipilimumab, Nivolumab, Sacituzumab govitecan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01222676
- Testing
- cisplatin, gemcitabine hydrochloride, sorafenib tosylate
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bladder Cancer
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
Purpose：To evaluate whether immediate multiparametric MRI evaluate the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer（MIBC）.
- Trial name
- NCT04588168
- Testing
- Chemotherapy, Immediate Multiparametric MRI, Cystectomy and Lymphadenectomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Transitional Cell Carcinoma Stage IV
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or…
- Trial name
- JASINT1 (NCT01599013)
- Testing
- Vinflunine, Gemcitabine, Vinflunine, Carboplatin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Pierre Fabre Medicament
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00028860
- Testing
- filgrastim, carboplatin, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Tulane University Health Sciences Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003105
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Metastatic Bladder Cancer
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective.
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
- Trial name
- NCT06138561
- Testing
- Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer, Urothelial Carcinoma
Bladder Cancer Screening Trial
There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Hematuria, Smoking Cessation
- Trial name
- NCT05646485
- Testing
- Urinalysis
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Texas Southwestern Medical Center